GSK halts Promacta trial on blood clot concerns; Resverlogix modifies trial enrollment; Lee Rauch named new CEO of Nuon;

 @FierceBiotech: Troubled Genzyme launches probe into insider trading claims. Article | Follow @FierceBiotech

 @JohnCFierce: 15 VC-backed companies traded hands last week. So is the party back on yet? Nope. Report  | Follow @JohnCFierce

> The FDA has noted that a clinical trial of GlaxoSmithKline's Promacta was halted after researchers spotted a higher rate of blood clots among patients taking the drug compared with the placebo arm. Promacta had been in a trial for chronic immune idiopathic thrombocytopenic purpura triggered by no known cause. The trial involved patients with ITP triggered by liver damage. Story

> Resverlogix says it has halted enrollment in a clinical trial to test a treatment for thickening of the arteries. The developer says it wants to modify its enrollment procedures, news that sent its shares down about 7 percent. Report

> Nuon Therapeutics named Lee Rauch president and CEO. Recently, she held the position of acting head of corporate development for Onyx Pharmaceuticals. Nuon release

> Colorado State University has opened a new, $53 million life sciences incubator. Report

> Irvine, CA-based Cobalis has named Martin Marion as its new chief executive officer. Cobalis release

And Finally... Walgreens has dropped the idea of selling a genetic home test after the FDA opened an investigation of the supplier, Pathway Genetics, and its product. Report